




PHARMACEUTICAL 2021

Biostax Corp.
Rank 378 of 402





PHARMACEUTICAL 2021

Biostax Corp.
Rank 378 of 402



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 194% points.

The company's Economic Capital Ratio, given in the ranking table, is -359%, being 406% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	10.0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,677
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	0.64
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	126
Selling, General and Administrative Expense	760

Output Variable	Value in 1000 USD
Assets	10
Liabilities	11,677
Expenses	887
Revenues	0
Stockholders Equity	-11,667
Net Income	-887
Comprehensive Net Income	-887
Economic Capital Ratio	-359%